Concepts (227)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Nanoparticles | 16 | 2022 | 318 | 3.330 |
Why?
|
| Drug Carriers | 14 | 2020 | 125 | 2.510 |
Why?
|
| Antineoplastic Agents | 13 | 2018 | 803 | 2.310 |
Why?
|
| Lung Neoplasms | 12 | 2018 | 358 | 2.240 |
Why?
|
| Drug Delivery Systems | 11 | 2022 | 202 | 2.200 |
Why?
|
| RNA, Small Interfering | 5 | 2018 | 409 | 1.970 |
Why?
|
| Noscapine | 6 | 2016 | 11 | 1.860 |
Why?
|
| Nanostructures | 7 | 2020 | 134 | 1.840 |
Why?
|
| Liposomes | 7 | 2015 | 118 | 1.540 |
Why?
|
| Polymers | 5 | 2022 | 121 | 1.490 |
Why?
|
| Neoplasms | 6 | 2022 | 1103 | 1.330 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 7 | 2017 | 88 | 1.310 |
Why?
|
| Nanocapsules | 3 | 2017 | 17 | 1.230 |
Why?
|
| Powders | 9 | 2019 | 17 | 1.200 |
Why?
|
| Particle Size | 18 | 2021 | 215 | 1.190 |
Why?
|
| Lung | 7 | 2019 | 446 | 1.150 |
Why?
|
| Aerosols | 8 | 2017 | 48 | 1.000 |
Why?
|
| Deoxycytidine | 2 | 2017 | 22 | 0.980 |
Why?
|
| Nanomedicine | 4 | 2022 | 35 | 0.890 |
Why?
|
| Biopharmaceutics | 1 | 2022 | 1 | 0.880 |
Why?
|
| Biocompatible Materials | 1 | 2022 | 76 | 0.830 |
Why?
|
| Delayed-Action Preparations | 4 | 2019 | 60 | 0.750 |
Why?
|
| Chemistry, Pharmaceutical | 9 | 2017 | 71 | 0.700 |
Why?
|
| Angiogenesis Inhibitors | 3 | 2019 | 59 | 0.680 |
Why?
|
| Drug Compounding | 7 | 2019 | 76 | 0.660 |
Why?
|
| Nebulizers and Vaporizers | 3 | 2009 | 19 | 0.660 |
Why?
|
| Administration, Inhalation | 10 | 2021 | 80 | 0.650 |
Why?
|
| Ethers | 1 | 2018 | 20 | 0.640 |
Why?
|
| Cell Line, Tumor | 12 | 2018 | 2231 | 0.620 |
Why?
|
| Alzheimer Disease | 3 | 2020 | 905 | 0.610 |
Why?
|
| Freeze Drying | 4 | 2021 | 27 | 0.610 |
Why?
|
| Cell Survival | 6 | 2016 | 864 | 0.610 |
Why?
|
| Antitussive Agents | 2 | 2014 | 4 | 0.590 |
Why?
|
| Acrylamide | 1 | 2016 | 7 | 0.580 |
Why?
|
| Benzofurans | 1 | 2016 | 21 | 0.570 |
Why?
|
| Humans | 38 | 2022 | 37093 | 0.560 |
Why?
|
| Arginine | 1 | 2016 | 73 | 0.560 |
Why?
|
| Plant Preparations | 1 | 2016 | 27 | 0.530 |
Why?
|
| Animals | 29 | 2022 | 15081 | 0.530 |
Why?
|
| Xenograft Model Antitumor Assays | 9 | 2016 | 259 | 0.520 |
Why?
|
| Diagnostic Imaging | 1 | 2015 | 53 | 0.510 |
Why?
|
| Drug Synergism | 6 | 2016 | 177 | 0.510 |
Why?
|
| Drug Discovery | 1 | 2016 | 82 | 0.500 |
Why?
|
| Mannose | 2 | 2016 | 25 | 0.490 |
Why?
|
| Intestinal Absorption | 1 | 2014 | 20 | 0.480 |
Why?
|
| STAT6 Transcription Factor | 1 | 2013 | 16 | 0.470 |
Why?
|
| Neovascularization, Pathologic | 2 | 2011 | 127 | 0.460 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 3 | 2013 | 182 | 0.450 |
Why?
|
| Serum Albumin, Bovine | 1 | 2013 | 51 | 0.450 |
Why?
|
| Nanotechnology | 6 | 2022 | 153 | 0.430 |
Why?
|
| Mesothelioma | 1 | 2014 | 144 | 0.430 |
Why?
|
| Pharmaceutical Preparations | 4 | 2015 | 75 | 0.410 |
Why?
|
| Selenium | 1 | 2013 | 148 | 0.390 |
Why?
|
| Cisplatin | 2 | 2016 | 72 | 0.390 |
Why?
|
| Adenocarcinoma | 1 | 2013 | 251 | 0.390 |
Why?
|
| Mice | 14 | 2022 | 5913 | 0.370 |
Why?
|
| Doxorubicin | 1 | 2011 | 84 | 0.370 |
Why?
|
| Apoptosis | 5 | 2011 | 1398 | 0.370 |
Why?
|
| MicroRNAs | 1 | 2014 | 426 | 0.330 |
Why?
|
| Dapsone | 1 | 2008 | 2 | 0.320 |
Why?
|
| Tacrolimus | 1 | 2007 | 10 | 0.290 |
Why?
|
| Amiloride | 1 | 2006 | 18 | 0.280 |
Why?
|
| Indoles | 4 | 2014 | 158 | 0.280 |
Why?
|
| Biological Availability | 6 | 2018 | 88 | 0.280 |
Why?
|
| Polyethylene Glycols | 2 | 2018 | 84 | 0.280 |
Why?
|
| Solubility | 5 | 2018 | 118 | 0.280 |
Why?
|
| Mice, Nude | 6 | 2014 | 337 | 0.270 |
Why?
|
| Gelatin | 2 | 2017 | 15 | 0.260 |
Why?
|
| Cells, Cultured | 3 | 2014 | 1518 | 0.250 |
Why?
|
| Hydrogen-Ion Concentration | 2 | 2016 | 364 | 0.240 |
Why?
|
| Tissue Distribution | 4 | 2019 | 207 | 0.230 |
Why?
|
| Caspase 3 | 4 | 2011 | 207 | 0.220 |
Why?
|
| Rats | 7 | 2019 | 3483 | 0.220 |
Why?
|
| Brain | 3 | 2020 | 1346 | 0.220 |
Why?
|
| Cancer Vaccines | 1 | 2022 | 21 | 0.220 |
Why?
|
| Lipids | 4 | 2020 | 235 | 0.220 |
Why?
|
| Nanocomposites | 1 | 2022 | 19 | 0.210 |
Why?
|
| Heparin | 1 | 2022 | 35 | 0.210 |
Why?
|
| Virus Diseases | 1 | 2021 | 22 | 0.200 |
Why?
|
| Biological Transport | 2 | 2018 | 185 | 0.190 |
Why?
|
| Technology, Pharmaceutical | 3 | 2017 | 27 | 0.190 |
Why?
|
| Taxoids | 2 | 2013 | 37 | 0.190 |
Why?
|
| X-Ray Diffraction | 2 | 2018 | 57 | 0.190 |
Why?
|
| RNA-Binding Proteins | 1 | 2022 | 146 | 0.190 |
Why?
|
| DNA Fragmentation | 2 | 2011 | 92 | 0.190 |
Why?
|
| RNA | 1 | 2022 | 241 | 0.180 |
Why?
|
| Breast Neoplasms | 1 | 2011 | 1502 | 0.180 |
Why?
|
| Wet Macular Degeneration | 1 | 2019 | 3 | 0.170 |
Why?
|
| Blood-Brain Barrier | 2 | 2018 | 162 | 0.170 |
Why?
|
| Apoptosis Regulatory Proteins | 2 | 2011 | 147 | 0.170 |
Why?
|
| Cell Proliferation | 2 | 2018 | 1198 | 0.170 |
Why?
|
| Methylcellulose | 1 | 2018 | 6 | 0.170 |
Why?
|
| Nifedipine | 1 | 2018 | 10 | 0.170 |
Why?
|
| Excipients | 1 | 2018 | 22 | 0.160 |
Why?
|
| Calcium Channel Blockers | 1 | 2018 | 56 | 0.160 |
Why?
|
| Rhodamines | 1 | 2018 | 21 | 0.160 |
Why?
|
| Nose | 1 | 2018 | 15 | 0.160 |
Why?
|
| Tablets | 1 | 2017 | 9 | 0.150 |
Why?
|
| Desiccation | 2 | 2008 | 10 | 0.150 |
Why?
|
| Models, Theoretical | 1 | 2019 | 217 | 0.150 |
Why?
|
| Calorimetry, Differential Scanning | 1 | 2017 | 30 | 0.150 |
Why?
|
| Viscosity | 1 | 2017 | 38 | 0.150 |
Why?
|
| Caco-2 Cells | 2 | 2014 | 52 | 0.150 |
Why?
|
| Oxidation-Reduction | 1 | 2018 | 431 | 0.140 |
Why?
|
| Metabolic Clearance Rate | 2 | 2007 | 25 | 0.140 |
Why?
|
| Etoposide | 1 | 2016 | 22 | 0.140 |
Why?
|
| Dendrimers | 1 | 2015 | 13 | 0.130 |
Why?
|
| Plants, Medicinal | 1 | 2016 | 68 | 0.130 |
Why?
|
| Phytotherapy | 1 | 2016 | 81 | 0.130 |
Why?
|
| Pyrazoles | 2 | 2013 | 85 | 0.130 |
Why?
|
| Sulfonamides | 2 | 2013 | 80 | 0.130 |
Why?
|
| Skin Diseases | 1 | 2015 | 31 | 0.130 |
Why?
|
| Receptor, EphA2 | 1 | 2014 | 6 | 0.120 |
Why?
|
| Powder Diffraction | 1 | 2013 | 1 | 0.120 |
Why?
|
| RNA Stability | 1 | 2013 | 26 | 0.120 |
Why?
|
| Dogs | 1 | 2014 | 149 | 0.120 |
Why?
|
| Molecular Weight | 1 | 2013 | 167 | 0.110 |
Why?
|
| Gene Transfer Techniques | 1 | 2013 | 47 | 0.110 |
Why?
|
| Spectrophotometry, Ultraviolet | 1 | 2013 | 98 | 0.110 |
Why?
|
| Chitosan | 1 | 2013 | 36 | 0.110 |
Why?
|
| Cyclooxygenase 2 Inhibitors | 1 | 2013 | 25 | 0.110 |
Why?
|
| Polymerase Chain Reaction | 1 | 2014 | 448 | 0.110 |
Why?
|
| Multivariate Analysis | 1 | 2014 | 583 | 0.110 |
Why?
|
| Rats, Sprague-Dawley | 2 | 2014 | 1618 | 0.100 |
Why?
|
| Porosity | 2 | 2022 | 32 | 0.100 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2011 | 20 | 0.100 |
Why?
|
| Female | 8 | 2013 | 20969 | 0.100 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2014 | 421 | 0.100 |
Why?
|
| Immunoenzyme Techniques | 1 | 2011 | 108 | 0.100 |
Why?
|
| Anticarcinogenic Agents | 1 | 2012 | 65 | 0.100 |
Why?
|
| Angiogenesis Inducing Agents | 1 | 2011 | 9 | 0.100 |
Why?
|
| Administration, Oral | 3 | 2019 | 224 | 0.100 |
Why?
|
| Biomedical Research | 1 | 2015 | 400 | 0.090 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2011 | 161 | 0.090 |
Why?
|
| Blotting, Western | 1 | 2011 | 859 | 0.080 |
Why?
|
| Amikacin | 1 | 2009 | 2 | 0.080 |
Why?
|
| Immunohistochemistry | 1 | 2011 | 893 | 0.080 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2013 | 807 | 0.080 |
Why?
|
| NF-kappa B | 1 | 2011 | 339 | 0.080 |
Why?
|
| Microscopy, Electron, Scanning | 3 | 2019 | 142 | 0.080 |
Why?
|
| Emulsions | 2 | 2019 | 33 | 0.080 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2008 | 112 | 0.080 |
Why?
|
| Clinical Trials as Topic | 1 | 2009 | 204 | 0.070 |
Why?
|
| Anti-Infective Agents | 1 | 2008 | 64 | 0.070 |
Why?
|
| Patents as Topic | 1 | 2007 | 14 | 0.070 |
Why?
|
| Rheology | 1 | 2007 | 25 | 0.070 |
Why?
|
| Materials Testing | 1 | 2007 | 69 | 0.070 |
Why?
|
| Sodium Channel Blockers | 1 | 2006 | 17 | 0.070 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2008 | 110 | 0.070 |
Why?
|
| Mice, Inbred BALB C | 3 | 2014 | 661 | 0.070 |
Why?
|
| Immunosuppressive Agents | 1 | 2007 | 76 | 0.070 |
Why?
|
| Adjuvants, Pharmaceutic | 1 | 2006 | 4 | 0.070 |
Why?
|
| Clobetasol | 1 | 2005 | 1 | 0.060 |
Why?
|
| Eczema | 1 | 2005 | 4 | 0.060 |
Why?
|
| Amphotericin B | 1 | 2005 | 24 | 0.060 |
Why?
|
| Mycoses | 1 | 2005 | 30 | 0.060 |
Why?
|
| Skin | 1 | 2005 | 174 | 0.060 |
Why?
|
| Crystallization | 2 | 2018 | 86 | 0.060 |
Why?
|
| Silicon Dioxide | 1 | 2022 | 34 | 0.050 |
Why?
|
| Partial Thromboplastin Time | 1 | 2022 | 8 | 0.050 |
Why?
|
| Mammals | 1 | 2022 | 105 | 0.050 |
Why?
|
| Immunotherapy | 1 | 2022 | 95 | 0.050 |
Why?
|
| Signal Transduction | 1 | 2010 | 1908 | 0.050 |
Why?
|
| Anticoagulants | 1 | 2022 | 102 | 0.050 |
Why?
|
| Acrylic Resins | 1 | 2019 | 7 | 0.040 |
Why?
|
| Goats | 1 | 2019 | 19 | 0.040 |
Why?
|
| Metronidazole | 1 | 2019 | 13 | 0.040 |
Why?
|
| Diffusion | 1 | 2019 | 50 | 0.040 |
Why?
|
| Cellulose | 1 | 2019 | 14 | 0.040 |
Why?
|
| Alginates | 1 | 2019 | 11 | 0.040 |
Why?
|
| Hyaluronic Acid | 1 | 2019 | 33 | 0.040 |
Why?
|
| Microspheres | 1 | 2019 | 49 | 0.040 |
Why?
|
| Visual Acuity | 1 | 2019 | 97 | 0.040 |
Why?
|
| Principal Component Analysis | 1 | 2019 | 89 | 0.040 |
Why?
|
| Drug Storage | 1 | 2018 | 27 | 0.040 |
Why?
|
| Hydrogels | 1 | 2019 | 37 | 0.040 |
Why?
|
| Spectroscopy, Fourier Transform Infrared | 1 | 2018 | 68 | 0.040 |
Why?
|
| Surface Properties | 1 | 2019 | 130 | 0.040 |
Why?
|
| Galantamine | 1 | 2018 | 2 | 0.040 |
Why?
|
| Mucociliary Clearance | 1 | 2018 | 5 | 0.040 |
Why?
|
| Risperidone | 1 | 2018 | 5 | 0.040 |
Why?
|
| Deferoxamine | 1 | 2018 | 19 | 0.040 |
Why?
|
| Nasal Mucosa | 1 | 2018 | 29 | 0.040 |
Why?
|
| Administration, Intranasal | 1 | 2018 | 79 | 0.040 |
Why?
|
| Poly(ADP-ribose) Polymerases | 2 | 2009 | 78 | 0.040 |
Why?
|
| Central Nervous System Diseases | 1 | 2018 | 29 | 0.040 |
Why?
|
| Olfactory Bulb | 1 | 2018 | 48 | 0.040 |
Why?
|
| Mechanical Phenomena | 1 | 2017 | 9 | 0.040 |
Why?
|
| Models, Biological | 2 | 2012 | 677 | 0.040 |
Why?
|
| Mice, Inbred C57BL | 1 | 2022 | 1609 | 0.040 |
Why?
|
| Time Factors | 2 | 2016 | 1742 | 0.040 |
Why?
|
| Water | 1 | 2018 | 296 | 0.030 |
Why?
|
| Models, Animal | 1 | 2016 | 134 | 0.030 |
Why?
|
| Drug Stability | 1 | 2016 | 116 | 0.030 |
Why?
|
| Skin Absorption | 1 | 2015 | 15 | 0.030 |
Why?
|
| Administration, Cutaneous | 1 | 2015 | 43 | 0.030 |
Why?
|
| PPAR gamma | 1 | 2014 | 53 | 0.030 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2016 | 222 | 0.030 |
Why?
|
| Endocytosis | 1 | 2014 | 113 | 0.030 |
Why?
|
| Oligopeptides | 1 | 2013 | 102 | 0.030 |
Why?
|
| Male | 4 | 2019 | 20025 | 0.030 |
Why?
|
| Ligands | 1 | 2014 | 349 | 0.030 |
Why?
|
| Injections, Intravenous | 1 | 2012 | 62 | 0.030 |
Why?
|
| Permeability | 1 | 2012 | 67 | 0.030 |
Why?
|
| Protein Binding | 1 | 2014 | 972 | 0.020 |
Why?
|
| Disease Models, Animal | 1 | 2016 | 1371 | 0.020 |
Why?
|
| Dosage Forms | 1 | 2010 | 2 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2012 | 550 | 0.020 |
Why?
|
| Feasibility Studies | 1 | 2010 | 208 | 0.020 |
Why?
|
| Capsules | 1 | 2009 | 25 | 0.020 |
Why?
|
| Neoplasm Transplantation | 1 | 2009 | 122 | 0.020 |
Why?
|
| bcl-2-Associated X Protein | 1 | 2008 | 77 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2008 | 152 | 0.020 |
Why?
|
| Aged | 1 | 2018 | 6741 | 0.020 |
Why?
|
| Tobramycin | 1 | 2006 | 3 | 0.020 |
Why?
|
| Mathematical Computing | 1 | 2006 | 9 | 0.020 |
Why?
|
| Poloxamer | 1 | 2006 | 9 | 0.020 |
Why?
|
| Neoplasm Proteins | 1 | 2008 | 213 | 0.020 |
Why?
|
| Leucine | 1 | 2006 | 29 | 0.020 |
Why?
|
| Micelles | 1 | 2005 | 32 | 0.020 |
Why?
|
| Cadaver | 1 | 2005 | 42 | 0.020 |
Why?
|
| Models, Chemical | 1 | 2006 | 207 | 0.020 |
Why?
|
| Double-Blind Method | 1 | 2005 | 286 | 0.020 |
Why?
|
| Microbial Sensitivity Tests | 1 | 2005 | 201 | 0.020 |
Why?
|
| Temperature | 1 | 2005 | 286 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2005 | 1039 | 0.010 |
Why?
|
| Inflammation | 1 | 2005 | 618 | 0.010 |
Why?
|